Ultrasound model identifies NAFLD patients with advanced fibrosis
A model using ultrasonic biomarkers could help physicians identify patients with nonalcoholic fatty liver disease (NAFLD) who have advanced fibrosis, a study presented November 30 at the RSNA 2023 annual meeting found.
In his presentation, Katsutoshi Sugimoto, MD, PhD, from Tokyo Medical University in Japan discussed the performance of a model he and colleagues developed, which combines multiparametric ultrasound markers. They found that combining normalized local variance with shear-wave speed improves assessment of advanced liver fibrosis.
“The combination…improved the diagnostic performance of identifying [disease...
Source: AuntMinnie.com Headlines - December 6, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Ultrasound Source Type: news
89bio Outlines Roadmap For Pivotal Studies For Lead Program In Fatty Liver Disease
89bio Inc ETNB announced a successful end-of-Phase 2 Meeting with the FDA supporting the advancement of pegozafermin into Phase 3 in nonalcoholic steatohepatitis (NASH). The program will include two Phase 3 trials evaluating patients with NASH: • ENLIGHTEN-Cirrhosis trial will enroll patients with…#incetnb #fda #phase3 #enlightencirrhosis #f2f3 #ema #enlightenfibrosis #glp1 (Source: Reuters: Health)
Source: Reuters: Health - December 4, 2023 Category: Consumer Health News Source Type: news
Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes
Carmot Therapeutics ’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in combination with Roche ’s in-house assetsLead asset CT-388 is a Phase-2 ready dual GLP-1/GIP agonist with best-in-class potential for the treatment of obesity and its comorbiditiesUnder the terms of the agreement, Roche will pay a purchase price of USD 2.7 billion upfront and additional milestone payments of up to USD 400 millionBasel, 4 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive merger a...
Source: Roche Investor Update - December 4, 2023 Category: Pharmaceuticals Source Type: news
Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes
Carmot Therapeutics ’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in combination with Roche ’s in-house assetsLead asset CT-388 is a Phase-2 ready dual GLP-1/GIP agonist with best-in-class potential for the treatment of obesity and its comorbiditiesUnder the terms of the agreement, Roche will pay a purchase price of USD 2.7 billion upfront and additional milestone payments of up to USD 400 millionBasel, 4 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive merger a...
Source: Roche Media News - December 4, 2023 Category: Pharmaceuticals Source Type: news
With rise of GLP-1 drugs, Peninsula biopharma targets another approach to diabetes and obesity
The founder and CEO of the startup worked on groundbreaking hepatitis C drugs as well as less-successful "fatty liver" drugs at Gilead Sciences. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 21, 2023 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
Prevalence of NAFLD Set to Increase to 34.3 Percent in 2050
MONDAY, Nov. 20, 2023 -- The burden of nonalcoholic fatty liver disease (NAFLD) is predicted to continue increasing, according to a study presented at The Liver Meeting, the annual meeting of the American Association for the Study of Liver... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 20, 2023 Category: Pharmaceuticals Source Type: news
Ultrasound model predicts liver cancer risk
Thursday, November 30 | 2:20 p.m.-2:30 p.m. | R6-SSGI19-6 | Room E352A model integrating clinical and surveillance ultrasound features for patients at high risk of hepatocellular carcinoma will be presented in this session.In his talk, Yeun-Yoon Kim, MD, from Yonsei University in South Korea will present research that demonstrates how this model has superior performance compared with previously reported risk scoring systems in this area.Predicting risk for hepatocellular carcinoma would help with triaging and strategizing best treatment options. Models integrating ultrasound features are being developed to help with suc...
Source: AuntMinnie.com Headlines - November 14, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: 2023 Ultrasound Preview Source Type: news
Ultrasound platform effective evaluating hepatic steatosis
Thursday, November 30 | 1:30 p.m.-1:40 p.m. | R6-SSGI19-1 | Room E352Attendees will hear about the potential for ultrasound-derived fat fraction to be an alternative tool for MRI in assessing hepatic steatosis.Yi Dong, MD, from Fudan University in Shanghai, China, will present findings that show how ultrasound-derived fat fraction can detect hepatic steatosis using MRI-derived proton density fat fraction as the reference standard.Several ultrasound platforms now provide quantitative measures of hepatic steatosis. One of these is ultrasound-derived fat fraction, which combines attenuation and backscatter quantification. ...
Source: AuntMinnie.com Headlines - November 14, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: 2023 Ultrasound Preview Source Type: news
MASLD Predicted to Increase by 23% by Middle of the Century
(MedPage Today) -- BOSTON -- A mathematical model predicts that the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) -- formerly known as nonalcoholic fatty liver disease (NAFLD) -- will substantially increase... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 12, 2023 Category: Gastroenterology Source Type: news
Torrent, Zydus in co-marketing pact for liver disease drug Saroglitazar
Torrent Pharmaceuticals and Zydus Lifesciences formed a licensing and supply pact to co-market Saroglitazar Mg, the sole approved treatment for Non-Alcoholic Steato Hepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) in India. Under the agreement, Torrent gains semi-exclusive rights to market as VORXAR while Zydus continues marketing as Lipaglyn and Bilypsa. Licensing fees and milestone payments are part of the pact. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 10, 2023 Category: Pharmaceuticals Source Type: news
Should We End Obesity?
It’s unusual for a medication to become a household name; even more uncommon for its branding to become, like Advil, shorthand for an entire class of products; and rarest of all, for it to change not just U.S. medicine, but U.S. culture.
Ozempic has done all three.
Approved in 2017 as a type 2 diabetes medication, Ozempic has largely made its name—and a fortune for its manufacturer, Novo Nordisk—as a weight-loss aid. Novo Nordisk knew early on that diabetes patients often lost weight on the drug, but even company executives couldn’t have guessed how widely it would eventually take off as both ...
Source: TIME: Health - November 7, 2023 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Drugs feature healthscienceclimate Magazine TIME 2030 Wellbeing Source Type: news
Lupin, Zydus Lifesciences ink licensing, supply pact for Saroglitazar Mg
Lupin and Zydus Lifesciences entered into a licensing and supply agreement to co-market Saroglitazar Mg, an innovative drug approved by India's DCGI for treating non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Lupin will have semi-exclusive rights to co-market the product in India under the brand name LINVAS. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 3, 2023 Category: Pharmaceuticals Source Type: news
MR proton density fat fraction imaging helps predict liver health
MR proton density fat fraction (PDFF) imaging helps predict liver health, researchers have found.The MRI PDFF measure could improve patient care by giving clinicians a more accurate picture of liver disease, a team led by Tianyi Xia, MD, of Zhongda Hospital School of Medicine, Southeast University, in Nanjing, China. The study results were published October 24 in Radiology."We found … that liver MRI PDFF was a causal mediator between potential risk factors and several liver disease risks," the group wrote.Hepatic steatosis is one of the anatomic characteristics of nonalcoholic fatty liver disease, and it is the "leading ...
Source: AuntMinnie.com Headlines - October 25, 2023 Category: Radiology Authors: Kate Madden Yee Tags: Clinical News MRI Source Type: news
From NAFLD to MASLD: What's in a Name? From NAFLD to MASLD: What's in a Name?
Presentations at the European Association for the Study of Diabetes 2023 Annual Meeting in Hamburg, Germany, stressed the gravity of nonalcoholic fatty liver disease and the reasons for its new name.Medscape Diabetes & Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - October 11, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology Commentary Source Type: news
Fatty Liver: A Primary Care Approach Fatty Liver: A Primary Care Approach
Neil Skolnik reviews the latest guidelines for a condition that PCPs see a lot of but may be failing to notice.Medscape Family Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 9, 2023 Category: Consumer Health News Tags: Family Medicine/Primary Care Commentary Source Type: news
